Dr. Pandalai on the Efficacy of Cytoreductive Surgery Plus HIPEC in Colorectal Peritoneal Carcinomatosis

In Partnership With:

Partner | Cancer Centers | <b>UK Markey</b>

Prakash Pandalai, MD, discusses the efficacy of aggressive cytoreductive surgery plus heated intraperitoneal chemotherapy in colorectal peritoneal carcinomatosis.

Prakash Pandalai, MD, ​assistant professor of surgery, surgical oncologist, University of Kentucky, Markey Cancer Center, discusses the efficacy of aggressive cytoreductive surgery plus heated intraperitoneal chemotherapy (HIPEC) in colorectal peritoneal carcinomatosis.

Historically, patients with colorectal peritoneal carcinomatosis who are treated with chemotherapy alone ​typically have a median overall survival of less than 1 year, Pandalai says. Add​ing aggressive cytoreductive surgery and HIPEC ​to traditional chemotherapy ​can improve outcomes for these patients.

Single​- and multi-institutional series have demonstrated an improved median OS with this regimen ​in the range of 40​to 45 months, which is quite profound for these patients, Pandalai concludes.